Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Search

December 2002

Grasping the Impact of the Genetic Revolution

IT’S BEEN SEVEN MONTHS since healthcare futurist Rick J. Carlson shared his insights about the impending genomic/proteomic revolution at the Executive War College in NewnOrleans last May. A key theme of his message was that diagnostic services would be squarely in the middle of the coming genetics tidal wave. Carlson, President of Health Strategies Group […]

To access this post, you must purchase The Dark Report.

Grasping the Impact of the Genetic Revolution Read More »

Laboratories Sit Squarely Between New Genetics and Today’s Medicine

“Clinical laboratories and pathology groups are at the leading edge of the genetic revolution.” —Rick J. Carlson. CEO SUMMARY: Healthcare futurist Rick J. Carlson believes that knowledge of the human genome will trigger revolutionary changes in the American healthcare system. In particular, Carlson predicts consumers will drive the primary shift in the way healthcare services

To access this post, you must purchase The Dark Report.

Laboratories Sit Squarely Between New Genetics and Today’s Medicine Read More »

Patient Safety is Related to “Quality Management”

REMEMBER BACK IN 1997 WHEN LABORATORY COMPLIANCE PROGRAMS were mandated by Medicare officials? That was a big thing in the laboratory industry. Every laboratory organization in the United States scrambled to assess their laboratory’s operating practices, develop policies, and create a compliance manual that met regulatory requirements. THE DARK REPORT was first to predict this

To access this post, you must purchase The Dark Report.

Patient Safety is Related to “Quality Management” Read More »

Several Major Surprises Mark Events of 2002

CEO SUMMARY: It was a year when the two blood brothers got much bigger and expanded market share by buying their largest competitors. With patient safety as the goal, employers began active steps to force hospitals, physicians, and other healthcare providers to use quality management systems to reduce errors. Unpredictable in many ways, 2002 set

To access this post, you must purchase The Dark Report.

Several Major Surprises Mark Events of 2002 Read More »

Docs’ In-Office Testing Showing Mixed Trends

CEO SUMMARY: Despite the burdens of CLIA certification and reduced reimbursement for lab tests, many medical practice experts are advising doctors to expand in-office testing. However, diagnostic technologies for near-patient testing are still not robust enough to support this trend. Early attempts to expand testing in physicians’ office laboratories show the technology is still not

To access this post, you must purchase The Dark Report.

Docs’ In-Office Testing Showing Mixed Trends Read More »

Quiet Changes To Ripple Drugs-of-Abuse Market

CEO SUMMARY: Drugs-of-abuse (DOA) testing is an intensely-competitive market poised for significant change. Historically, national lab companies have been the major players and used rock-bottom prices to control the nation’s biggest corporate DOA clients. But since this line of testing yields meager profits at best, indications are that the nation’s two largest labs intend to

To access this post, you must purchase The Dark Report.

Quiet Changes To Ripple Drugs-of-Abuse Market Read More »

Tech Shortage Plays Role In More Drug Dosing Errors

INCORRECT ADMINISTRATION OF DRUGS is one major source of errors in hospitals and evidence indicates that children and emergency-room visitors are most likely to be affected. That’s the conclusion of a study done by U.S. Parmacopia’s Center for the Advancement of Patient Safety (CAPS). Researchers identified 105,603 medication errors during 2001 in 368 hospitals participating

To access this post, you must purchase The Dark Report.

Tech Shortage Plays Role In More Drug Dosing Errors Read More »

It’s a Feud in North Carolina! LabCorp Versus Spectrum

OVER IN NORTH CAROLINA, one of those good, old-fashioned southern feuds is under way. Like the fabled feud between the Hatfields and the McCoys of years past, Spectrum Laboratory Network and Laboratory Corporation are in a full-fledged shoot-out over market share of physicians’ office testing in the Tar Heel State. This feud is instructive in

To access this post, you must purchase The Dark Report.

It’s a Feud in North Carolina! LabCorp Versus Spectrum Read More »

“December 9, 2002 Intelligence: Late Breaking Lab News”

This morning AmeriPath, Inc. announced that it would be purchased by Welsh Carson Anderson & Stowe, a private equity firm based in New York City. Welsh Carson will pay $21.25 per share, a 30% premium over AmeriPath’s closing NASDAQ price of $16.45 on Friday, December 6.Welsh Carson already owns 4.9% of AmeriPath and will pay

To access this post, you must purchase The Dark Report.

“December 9, 2002 Intelligence: Late Breaking Lab News” Read More »

;